Your session is about to expire
← Back to Search
MK-8189 for Alzheimer's Disease
Study Summary
This trial will test a new drug for safety and tolerability in people with Alzheimer's, with or without symptoms of aggression and/or psychosis.
- Alzheimer's Disease
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 224 Patients • NCT03055338Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the trial open to geriatric individuals?
"The upper and lower bounds of this clinical trial are 65 and 85 years old, respectively. Eligible participants must be within these age brackets to qualify for enrollment."
In how many distinct venues is this trial currently being conducted?
"Currently, this clinical trial is being conducted across 8 different centres. Locations include Princeton, Staten Island and Miami with other cities housing the remainder of the sites. It may be beneficial to select the closest site in order to limit travel requirements if chosen as a participant."
Are there openings for me to join this clinical experiment?
"To be considered for this research, candidates must display aggression and satisfy the age requirement of 65 to 85. The clinical trial has the capacity to accept 28 participants."
Has the FDA approved MK-8189 for public use?
"Due to minimal safety and efficacy data, MK-8189 was given a rating of 1 on the Power scale."
Are there any current opportunities to join this scientific experiment?
"The clinical trial in question, which was initially posted on July 1st 2022 and subsequently updated on November 23rd 2022, is not seeking applicants at this time. Nevertheless, there are 610 other medical studies currently accepting patients."
Share this study with friends
Copy Link
Messenger